Q-omics provides the consensus-scored MVD profile across patient tissues and cancer cell-line models. MVD expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, MVD is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, MVD RNA expression shows 18,216 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UVM, COAD, and ACC as cancer lineages where MVD shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MVD — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MVD survival associations across molecular data types. MVD RNA expression shows survival associations in the most cancer types (27), followed by mutation status (2) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MVD RNA expression–survival associations across cancer types. High MVD expression shows unfavorable associations in ACC, LIHC, HNSC and BLCA, but favorable associations in UVM and UCEC. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify UVM as the clearest survival context for MVD RNA expression.
This table summarizes MVD tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 4. The strongest signals are observed in COAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MVD. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MVD shows lower tumor expression in THCA and LUAD and higher tumor expression in COAD, LIHC, BLCA and HNSC. The COAD box plot shows higher MVD RNA expression in tumor versus normal tissue (log2 FC = +1.263, t-test p < 0.001).
This table shows molecular features associated with MVD in patient tissues and cancer cell lines. In patient samples, MVD shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, MVD RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BONE.
